Ranitidine Effectively Relieves Symptoms in a Subset of Patients with Functional Dyspepsia

Farup, Per G.; Wetterhus, S; Osnes, M; Ulshagen, K.

doi:10.3109/00365529708996530

Cited by 22 publications

(28 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…24 We have demonstrated that there is no significant difference between responders and non-responders with regard to serum pepsinogen A, which significantly correlates with peak acid output, 8 whereas the pepsinogen A ⁄ C ratio in responders is significantly higher than that in non-responders. This ratio negatively correlates with the early morning gastric pH, 9 which may be related to basal acid output 6 . The response to antisecretory agents in patients with functional dyspepsia may depend on basal rather than peak acid output.…”

Section: Discussionmentioning

confidence: 97%

“…5 4 Moreover, Farup et al reported that it was not possible to determine H2RA responders on the basis of demographics, symptoms and signs in an investigation of 226 patients with functional dyspepsia. 6 Therefore, it is of clinical importance to categorize the population for whom H2RA provides benefit.…”

Section: Discussionmentioning

confidence: 99%

“…4 Currently, many dyspepsia patients are prescribed H2RAs or consume overthe-counter H2RAs on a trial-and-error basis, although many studies of H2RA therapy in the treatment of functional dyspepsia have shown it to be ineffective, except in a selected subgroup of patients. 5,6 Pepsinogen, the precursor of pepsin, exists as two main types: pepsinogen A and pepsinogen C. Pepsinogen A is produced by the chief and mucus neck cells in the gastric fundus. Pepsinogen C is also produced by the chief and mucus neck cells, and additionally by the pyloric glands in the antrum and Brunner's glands in the proximal duodenum.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serum pepsinogen can predict response to H2‐receptor antagonist in patients with functional dyspepsia

Yoshikawa

Murata

Kume

et al. 2002

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARYBackground: Therapy for the relief of symptoms of functional dyspepsia is unpredictable. Aim: To identify which patients may benefit from antisecretory therapy. Methods: Twenty-seven patients with functional dyspepsia were selected to receive H2-receptor antagonist (H2RA) treatment for 4 weeks. Serum pepsinogen A, pepsinogen C and gastrin were measured, and Helicobacter pylori status was determined. Symptoms were assessed at baseline and after H2RA treatment. Results: Fourteen patients were identified as H2RA responders and the remaining patients were non-responders. No differences were found between

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum pepsinogen can predict response to H2‐receptor antagonist in patients with functional dyspepsia

Yoshikawa

Murata

Kume

et al. 2002

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Several randomized controlled trials on the use of H 2 -receptor antagonists in FD have been published, but their efficacy is uncertain. Experience from everyday practice and clinical trials indicates that H 2 -receptor antagonists might be effective for a subset of patients with FD [29,30,31,32]. Therefore, it is of major clinical value to determine the characteristics of responders and nonresponders for any given treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Considering long-term use of PPI therapy in FD patients, the risk of minor side effects such as vitamin B 12 deficiency, Clostridium difficile -associated diarrhea and hip fracture have to be carefully assessed during treatment. Furthermore, the management of FD remains unsatisfactory except for a selected subgroup of patients [28,29]. Several randomized controlled trials on the use of H 2 -receptor antagonists in FD have been published, but their efficacy is uncertain.…”

Section: Discussionmentioning

confidence: 99%

Nizatidine Improves Clinical Symptoms and Gastric Emptying in Patients with Functional Dyspepsia Accompanied by Impaired Gastric Emptying

Futagami¹,

Shimpuku²,

Song³

et al. 2012

Digestion

View full text Add to dashboard Cite

Background/Aims: In this crossover study, we investigated whether nizatidine, a H₂-receptor antagonist, can alleviate clinical symptoms and gastric emptying in patients with Rome III-based functional dyspepsia (FD) with or without impaired gastric emptying. Methods: We enrolled 30 patients presenting with FD symptoms (epigastric pain syndrome, n = 6; postprandial distress syndrome, n = 24). Rome III-based FD patients were treated with nizatidine (300 mg/day) or placebo for 4 weeks in a crossover trial. Gastric motility was mainly evaluated with the T_max value using the ¹³C-acetate breath test. Meal-related symptoms were defined as postprandial fullness and early satiation. Gastroesophageal symptom was defined as a burning feeling rising from the stomach or lower chest up toward the neck. Acylated- and desacylated ghrelin levels were evaluated by the ELISA method. Clinical symptoms, gastric emptying and ghrelin levels were evaluated at three different points during the study (pretreatment, after 4 weeks former treatment and after 4 weeks later treatment). The primary end point of this study was to determine whether nizatidine would improve clinical symptoms and gastric emptying in FD patients with or without impaired gastric emptying via affecting ghrelin levels. Results: Meal-related symptoms of the patients treated with nizatidine improved significantly (21/30; 70%) compared to those treated with placebo (3/30; 10%). In addition, nizatidine treatment also significantly improved gastroesophageal symptoms (16/30; 53%) compared to those treated with placebo (0/30; 0%). Nizatidine treatment in patients with FD accompanied by impaired gastric emptying significantly improved clinical symptoms and T_max value as a marker of gastric emptying (10/11, 91%; 9/11, 82%) compared to placebo therapy, respectively. There were no significant differences in ghrelin levels between nizatidine treatment and placebo therapy. Conclusion: Nizatidine administration significantly improved both gastric emptying and clinical symptoms in FD patients with impaired gastric emptying.

show abstract

Pharmacological interventions for non-ulcer dyspepsia

Martin¹,

Soo²,

Deeks³

et al. 2005

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Ranitidine Effectively Relieves Symptoms in a Subset of Patients with Functional Dyspepsia

Abstract: Ranitidine has a good and clinically significant effect in a subset of patients with functional dyspepsia.

Cited by 22 publications

References 27 publications

Serum pepsinogen can predict response to H2‐receptor antagonist in patients with functional dyspepsia

Serum pepsinogen can predict response to H2‐receptor antagonist in patients with functional dyspepsia

Nizatidine Improves Clinical Symptoms and Gastric Emptying in Patients with Functional Dyspepsia Accompanied by Impaired Gastric Emptying

Pharmacological interventions for non-ulcer dyspepsia

Contact Info

Product

Resources

About